In contrast, in settings of autoimmunity, the fact that the absence or, in a therapeutic context, the blocking of the CD45 or CD148 axes modulates and partially hinders neutrophils from recruiting into tissues is presumably advantageous. The gene discussed is PTPRJ; the disease is Autoimmunity.